No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 154.5x · 10Y median 139.7x · 58th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 20
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:57:52.954Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Prime Medicine, Inc. (PRME) stock was $3.49 as of Oct 6, 2026, 1:55 PM EDT, up 8.57% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -49.0% · 3-year avg -28.8%/yr
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology.
Biotechnology · Cambridge, MA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 6, 2026
31 days away
EPS Estimate
-0.24
Revenue Est.
$1.32M
Last Quarter Results
EPS
$-0.24
vs Estimate
$-0.26
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PRME | $629.45M | $3.48 | +8.57% | -49.04% | N/A | N/A | N/A |
| 2SOPH | $634.15M | $7.56 | -7.82% | +85.81% | -13.62% | N/A | vs PRME |
| 3AURA | $634.46M | $6.13 | -1.39% | +2.80% | N/A | N/A | vs PRME |
| 4OABI | $639.31M | $4.41 | -10.37% | +200.25% | -13.17% | N/A | vs PRME |
| 5CLYM | $617.87M | $10.79 | -2.35% | +453.52% | N/A | N/A | vs PRME |
| 6STLN | $657.51M | $6.58 | +4.38% | N/A | N/A | N/A | vs PRME |
forward FY estimate
N/A
$1.15M
vs Estimate
$2.25M
Consensus Rating
Based on 11 analysts
Average Price Target
$7.11
+104.1% upside
Low
$4.25
Current
$3.48
High
$11.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.29 | $-0.24 | $-0.20 | 9 |
| Quarter ending Dec 2026 | $-0.30 | $-0.23 | $-0.16 | 9 |
| Quarter ending Mar 2027 | $-1.06 | $-0.26 | $0.05 | 6 |
| Quarter ending Jun 2027 | $-1.03 | $-0.25 | $0.04 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.11 | $-0.97 | $-0.81 | 11 |
| FY 2027 | $-1.11 | $-0.92 | $-0.71 | 10 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $267078.00 | $1.32M | $3.95M | 7 |
| Quarter ending Dec 2026 | $566710.00 | $6.13M | $20.91M | 7 |
| Quarter ending Mar 2027 | $115028.00 | $1.24M | $4.25M | 3 |
| Quarter ending Jun 2027 | $115028.00 | $1.24M | $4.25M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.42M | $8.86M | $35.40M | 10 |
| FY 2027 | $2.27M | $10.55M | $31.71M | 10 |
